Amphastar Pharmaceuticals, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.amphastar.com

Earnings Score
Moat Score
Safety Score

Market Cap $1.13B
PE 7
Debt $613.77M
Cash $151.84M
EV $1.60B
FCF $172.35M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$159.52M
EBIT	$205.42M
ROE	22%
ROA	13%
FCF	$172.35M
Equity	$732.30M
Growth Stability	-187%
PE	7.11
PEG	0.05
PB	1.55
P/FCF	6.58
P/S	1.55
Price/Cash	0.13
Debt/Equity	0.84
Debt/FCF	3.56
Net Margins	22%
Gross Margins	51%
Op. Margins	28%
Earnings CAGR	37%
Sales Growth YoY	5%
Sales Growth QoQ	-2%
Sales CAGR	15%
FCF CAGR	36%
Equity CAGR	10%
Earnings Stability	0.35
Earnings Growth YoY	5%
Earnings Growth QoQ	-6%

Earnings CAGR 5Y	129%
Sales CAGR 5Y	20%
FCF CAGR 5Y	69%
Equity CAGR 5Y	13%
Earnings CAGR 3Y	22%
Sales CAGR 3Y	22%
FCF CAGR 3Y	45%
Equity CAGR 3Y	18%
Market Cap	$1.13B
Revenue	$731.97M
Assets	$1.58B
Total Debt	$613.77M
Cash	$151.84M
Shares Outstanding	47.62M
EV	1.6B
Earnings Score	33%
Moat Score	95%
Safety Score	57%
Final Score	62%
Working Capital	360.31M
Current Ratio	3.07
Gross Profit	$373.86M
Shares Growth 3y	-0%
Equity Growth QoQ	1%
Equity Growth YoY	15%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

SEC Filings

Direct access to Amphastar Pharmaceuticals, Inc. (AMPH) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Amphastar Pharmaceuticals, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Amphastar Pharmaceuticals, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 37%

Stability 35%

loading chart...

Amphastar Pharmaceuticals, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Amphastar Pharmaceuticals, Inc..

Years

Calculation mode

= $21B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$172M	$234M	$319M	$434M	$590M	$803M	$1.1B	$1.5B	$2B	$2.8B	$3.7B	$37B
DCF		$213M	$264M	$326M	$403M	$499M	$617M	$763M	$943M	$1.2B	$1.4B	$14B
Value	$21B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-1%	4%	2%	-2%	14%	0%	14%	18%	21%	22%	22%
ROA	-	4%	0%	-2%	10%	2%	13%	16%	13%	13%	13%
ROE	-	3%	1%	-2%	11%	0%	14%	17%	22%	22%	22%

Good Net Margins (21.79%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	2.51	13.01	-7.94	261.18	2.49	1.14	1.22	4.15	3.56	3.56
Debt over Equity	0.18	0.13	0.16	0.19	0.13	0.13	0.18	0.15	0.94	0.84	0.84
Growth Stability	-	-	-	-187%	100%	8%	100%	100%	100%	100%	-187%

Neutral Debt/FCF ratio (3.56)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (0.84)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (-187%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	1%	-6%	23%	9%	9%	25%	14%	29%	14%	20%
Earnings YoY growth	-	-452%	-63%	-283%	-798%	-98%	6K%	47%	51%	16%	129%
Equity YoY growth	-	11%	2%	8%	17%	5%	-1%	19%	21%	15%	13%
FCF YoY growth	-	-560%	-76%	-310%	-102%	11K%	201%	-8%	123%	19%	69%